Skip to main content

Advertisement

Table 1 (abstract P191). Demographic and clinical characteristics of the JIA patients by therapy. Data are medians (1st –3rd quartiles) or frequencies (%).

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

  Adalimumab n=80 (54%) Etanercept n=36 (24%) Tocilizumab n=32 (22%) Total n=148
Age at onset, years 6.1 (3.1-10.4) 4.9 (1.9-9.7) 6.1 (3.8-9.1) 5.8 (2.7-10.1)
Age at JIA diagnosis, years 6.8 (3.3-11.9) 5.5 (2.1-10.6) 6.4 (4.1-9.2) 6.4 (3.2-11.0)
Disease duration, years 2.4 (0.9-4.8) `2.2 (1.1-5.5) 4.1 (1.4-6.5) 2.6 (1.1-5.8)
Female 60 (75.0) 26 (72.2) 23 (71.9) 109 (73.6)
ILAR JIA category
 Systemic 2 (2.5) 0 7 (21.9) 9 (6.1)
 Oligoarthritis 30 (37.5) 7 (19.4) 9 (28.1) 46 (31.1)
 Polyarthritis 27 (33.8) 23 (63.9) 13 (40.6) 63 (42.6)
 Psoriatic arthritis 1 (1.2) 0 0 1 (0.7)
 Enthesitis related arthritis 16 (20.0) 3 (8.3) 0 19 (12.8)
 Undifferentiated arthritis 4 (5.0) 3 (8.3) 3 (9.4) 10 (6.7)
Anti-Drug Antibodies* 14 (18%) - 3 (9%) 17 (11%)
Anti-Drug Antibodies** 5 (6%) - 2 (6%) 7 (5%)
JADAS 10
 M0 12.6 (7–17) 15.6 (10–18.5) 15.6 (11.6–23.2) 13.5 (8.5–18.3)
 M1 4 (1.5–6.5) 5.7 (3.4–12.7) 5.5 (3–11.4) 4.5 (2–8)
 M3 2.7 (1–5.9) 2.2 (0–7.7) 2.5 (0.7–6) 2.5 (0.5–5.9)
 M6 1.5 (0–5) 1 (0–8) 2 (0.5–7.5) 1.7 (0–5.8)
 M12 0.5 (0–5) 0.5 (0–4.2) 2 (0.5–4.5) 0.5 (0–4.7)
 ACR 70
  M1 30 (46.2) 8 (33.3) 5 (31.3) 43 (41.0)
  M3 40 (62.5) 17 (63.0) 10 (62.5) 67 (62.6)
  M6 41 (67.2) 18 (62.1) 13 (76.5) 72 (67.3)
  M12 42 (71.2) 19 (76.0) 13 (76.5) 74 (73.3)
  1. *in at least 1 determination ** in at least 2 determination